Arrowhead Pharmaceuticals, Inc. ARWR

Goldman Sachs resumed coverage on Arrowhead with a Neutral rating and $74 target, citing de-risked commercial execution and underappreciated pipeline optionality amid a biotech rally driven by acquisitions and positive clinical catalysts. Citi kept a Buy rating and $108 target and added ARWR to its upside 30-day catalyst watch ahead of upcoming clinical data. Arrowhead reported interim topline data from the Phase 1/2a ARO-DIMER-PA trial, with mean maximal single-dose reductions of 72% in PCSK9 and 88% in APOC3, to be presented at a medical congress. The company also acquired a FDA Rare Pediatric Disease Priority Review Voucher to pair with a potential supplemental NDA for plozasiran in severe hypertriglyceridemia, with submission planned by end-2026. In Q3, revenue rose to $75.3 million but net loss widened to $194.3 million; cash and investments total about $1.566 billion. SHASTA-3/SHASTA-4 met endpoints and near-term catalysts persist. Interim ARO-DIMER-PA data, a Rare Pediatric Disease Voucher, and multiple near-term catalysts create meaningful near-term upside and pipeline optionality.

RNA interference company ADARx Pharmaceuticals priced its $446.3 million IPO, selling about 26 million shares at $17 each, at the top end of its range. It also raised roughly $89 million in a private stock sale to AbbVie, its development partner. ADARx will trade on Nasdaq as ADRX. The company says RNAi remains challenged by delivery and potency, with most marketed drugs targeting the liver; ADARx aims at liver and other targets with optimized RNAi therapies for chronic conditions. Its lead candidate, onvuzosiran, is in late-stage testing for hereditary angioedema (HAE); early data showed up to 93% reduction in plasma kallikrein, a swelling trigger. Phase 3 readout is expected by end-2027. ADARx also targets mid-stage programs for agazisiran in kidney disease, geographic atrophy and paroxysmal nocturnal hemoglobinuria, plus other non-liver targets. AbbVie previously paid $335 million upfront in a collaboration. This marks the first RNAi-focused US IPO in about two years. ADARx IPO and AbbVie collaboration heighten RNAi competition and could affect ARWR's investor sentiment and relative valuation.

Arrowhead Pharmaceuticals releases ARO DIMER PA data and assesses whether the stock remains undervalued. ARO DIMER PA data directly affects pipeline progress and could shift company trajectory plus investor sentiment on valuation.

Arrowhead Pharmaceuticals highlights dual-target RNAi data and Plozasiran launch progress. Dual-target RNAi data and Plozasiran launch progress signal major pipeline advancements likely to alter company trajectory and investor sentiment.

Arrowhead Pharmaceuticals plans regulatory filing for SHTG treatment as its RNAi pipeline expands. Upcoming SHTG filing and RNAi pipeline growth signal major strategic progress that can significantly alter company trajectory.

Arrowhead Pharmaceuticals achieves clinical validation for its new drug platform. Clinical validation of new drug platform signals major strategic progress with strong potential to reshape pipeline and market trajectory.

Arrowhead forecasts gradual Redemplo sales growth to a $3-4B peak instead of a strong launch and stresses its broad pipeline. Modest Redemplo peak-sales guidance with pipeline emphasis points to limited shifts in revenue trajectory and sentiment.

Arrowhead Pharmaceuticals announced interim topline clinical data for its first dual-functional RNAi therapeutic targeting mixed hyperlipidemia. Clinical data release for novel RNAi therapeutic can drive major pipeline progress and investor revaluation.

ARWR stock heads for worst day in over a year after positive early-stage cholesterol drug data, with retail investors dismissing the release as sell-the-news reaction. Positive early-stage cholesterol drug data produces sharp negative stock reaction without altering long-term trajectory.

Arrowhead Pharmaceuticals presented SHASTA-3 and SHASTA-4 data at ESC 2026. SHASTA-3 and SHASTA-4 data at ESC 2026 signals major clinical progress for Arrowhead.

Arrowhead Pharmaceuticals reported a 78% lower pancreatitis event rate with plozasiran. Questions remain on whether the absolute benefit justifies a broader label. Positive plozasiran trial data could drive regulatory expansion and major shifts in company trajectory.

Arrowhead Pharmaceuticals receives FDA approval for a treatment yet the stock shows minimal movement as investors remain unimpressed. FDA approval constitutes a major regulatory milestone that can shift Arrowhead's commercial trajectory and investor outlook.

Arrowhead Pharmaceuticals' SHASTA 3 and SHASTA 4 data impress, prompting questions on whether ARWR stock is undervalued. Positive SHASTA 3 and 4 trial results can significantly boost ARWR's valuation and pipeline prospects.

Arrowhead’s Plozasiran reduced triglycerides and pancreatitis risk in Phase 3 trials. Positive Phase 3 data for Plozasiran signals major progress toward approval and revenue potential for ARWR.

Arrowhead Pharmaceuticals reported Phase 3 SHASTA-3 and SHASTA-4 data showing plozasiran reduced acute pancreatitis events in patients with severe hypertriglyceridemia. Positive Phase 3 results for plozasiran indicate strong potential for regulatory approval and revenue growth.

Arrowhead Pharmaceuticals' Plozasiran may act as catalyst for major stock re-rating. Plozasiran development represents major strategic product advance likely to significantly shift company trajectory and investor views.

Arrowhead Pharmaceuticals' REDEMPLO® (plozasiran) is now available in Germany for familial chylomicronaemia syndrome patients as a treatment to reduce triglycerides. German market access for plozasiran enables commercial sales of Arrowhead's FCS therapy and supports European revenue growth.

Arrowhead Pharmaceuticals acquires Priority Review Voucher to enable sNDA submission for Plozasiran in severe hypertriglyceridemia. PRV acquisition directly speeds FDA review timeline for key pipeline asset Plozasiran and supports faster commercialization.

Arrowhead Pharmaceuticals highlighted strong Phase III data in its Q3 2026 earnings call. Strong Phase III data signals major progress toward regulatory approval and revenue growth.

Arrowhead Pharmaceuticals, Inc. acquires an FDA Priority Review Voucher. Acquisition of FDA Priority Review Voucher enables faster drug approval timelines potentially boosting company performance.

Arrowhead Pharmaceuticals Q3 earnings call covered financial results, pipeline progress on RNAi drugs, and upcoming milestones for candidates in liver and pulmonary diseases. Q3 earnings call updates on finances and pipeline provide moderate short-term influence on stock sentiment and operations outlook.

Arrowhead Pharmaceuticals reported financial results for fiscal 2026 third quarter. Quarterly results update financial performance and may shift near-term investor sentiment.

Arrowhead Pharmaceuticals may see its bullish outlook shift after dual Phase 3 RNAi cardiometabolic milestones. Dual Phase 3 milestones in core cardiometabolic RNAi programs can materially advance the pipeline and reset market views on Arrowhead.

Arrowhead Pharmaceuticals completed enrollment in its global Phase 3 YOSEMITE study of Zodasiran for homozygous familial hypercholesterolemia treatment. Phase 3 enrollment completion advances Zodasiran development and supports potential future therapy revenue.

Arrowhead Pharmaceuticals transitions to commercial company operations, raising questions on whether its stock represents a smart buy amid this shift. Transition to commercial operations marks major strategic move likely to significantly alter company trajectory and investor sentiment.

ARWR shares posted their best session in nearly eight months after an analyst raised the price target on positive Plozasiran data. Analyst price target increase tied to Plozasiran data triggered major stock gains and improved market sentiment toward Arrowhead's pipeline.

Arrowhead Pharmaceuticals stock surged after a best-case scenario unfolded in its pipeline developments, driving sharp gains and positive investor sentiment around upcoming milestones. Stock surge reflects major positive development likely to boost near-term valuation and pipeline visibility for Arrowhead.

Arrowhead Pharmaceuticals stock hits new highs as Plozasiran advances toward expanded commercialization. Plozasiran nearing commercialization drives major gains and strategic growth for Arrowhead.

Arrowhead Pharmaceuticals shares surged on positive pipeline momentum and competitive gains while rival Ionis Pharmaceuticals stock fell sharply after setbacks in its drug development program. Arrowhead's sharp stock rise against its main rival directly reflects material shifts in competitive positioning and investor sentiment that can alter near-term valuation and partnership prospects.

Arrowhead Pharmaceuticals stock nears over 5-year highs after Phase 3 breakthrough, with retail investors cheering the push for broader FDA approval. Phase 3 success and broader FDA approval efforts drive major gains in company trajectory and investor sentiment.